Program
Allogeneic Invariant Natural Killer T-cells agenT-797
Also written as “agenT-797” and “Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797)”.
Its studies are mostly in Respiratory Distress Syndrome · Pneumonia · Neoplasms · Multiple Myeloma, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Agenus | 30 open or running | phase 1since Oct 6, 2020 | Oct 6, 2020 | none ahead |
| ImmunityBio | 10 open or running | phase 2since Mar 13, 2026 | Mar 13, 2026 | none ahead |
| MiNK Therapeutics | 11 open or running | phase 2since May 22, 2026 | May 22, 2026 | Jun 2027phase 2 · NCT07615010 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 6, 2020First study: phase 1 study in Respiratory Distress SyndromeNew to AgenusAgenus · NCT04582201 · 20 enrolled · United States
- Feb 3, 2021Phase 1 study in Multiple MyelomaAgenus · NCT04754100 · 13 enrolled · United States
- Oct 12, 2021Phase 1 study in NeoplasmsAgenus · NCT05108623 · 34 enrolled · United States
- Mar 13, 2026ImmunityBio’s first study: phase 2 study in Respiratory Distress SyndromeNew to ImmunityBioImmunityBio · NCT07492888
- May 22, 2026MiNK Therapeutics’ first study: phase 2 study in PneumoniaNew to MiNK TherapeuticsMiNK Therapeutics · NCT07615010 · 90 planned · United States, Ukraine
Ahead
- Jun 2027Primary completion: phase 2 study in PneumoniaMiNK Therapeutics · NCT07615010
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07615010Pneumonia · United States, Ukraine | 2 | Recruiting | MiNK Therapeutics | Jun 2027 | 90 |
| NCT07492888Respiratory Distress Syndrome | 2 | Withdrawn | ImmunityBio | Nov 15, 2026 | 0 |
| NCT05108623Neoplasms · United States | 1 | Completed | Agenus | Jan 2, 2024 | 34 |
| NCT04754100Multiple Myeloma · United States | 1 | Completed | Agenus | Jan 13, 2023 | 13 |
| NCT04582201Respiratory Distress Syndrome · United States | 1 | Completed | Agenus | Apr 23, 2023 | 20 |
How it is read
Names in the registry
- “agenT-797”, 4 entries
- “Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797)”, 1 entry
Conditions, from the studies’ own filings
- Respiratory Distress Syndrome, 2 studies
- Pneumonia, 1 study
- Neoplasms, 1 study
- Multiple Myeloma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.